At Cadence, we know that it’s important for you to know the entire oncology landscape as you proceed with your own assets, and our Medical Content team is scanning it for you.

More than 40 clinical trials in over a dozen indications with more than fifteen investigational and commercialized molecules is evidence of the explosion of immune checkpoint inhibitors in the field of oncology. With our white paper, you’ll get a crash course in this dynamic area, combining history lessons with future expectations.

PDF click to download2017 May White Paper: Immune Checkpoint Inhibitors

Zachary Moore

Author Zachary Moore

More posts by Zachary Moore